UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 46

Sortiert nach

Structure of the human marker of self 5-transmembrane receptor CD47

Nature communications, 2021-09, Vol.12 (1), p.5218-5218, Article 5218

2021

Link zum Volltext

Verfügbarkeit prüfen

Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody

Cancer Immunology, Immunotherapy, 2022-02, Vol.71 (2), p.473-489

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs

PloS one, 2020-03, Vol.15 (3), p.e0229445-e0229445

2020

Link zum Volltext

Verfügbarkeit prüfen

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma

mAbs, 2024, Vol.16 (1), p.2310248-2310248

2024

Link zum Volltext

Verfügbarkeit prüfen

Emerging antibody combinations in oncology

mAbs, 2011-07, Vol.3 (4), p.338-351

2011

Link zum Volltext

Verfügbarkeit prüfen

Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions

Clinical cancer research, 2009-11, Vol.15 (21), p.6582-6594

2009

Link zum Volltext

Verfügbarkeit prüfen

Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response

Molecular cancer therapeutics, 2010-09, Vol.9 (9), p.2593-2604

2010

Link zum Volltext

Verfügbarkeit prüfen

Stable IgG-like Bispecific Antibodies Directed toward the Type I Insulin-like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-tumor Activity

The Journal of biological chemistry, 2011-02, Vol.286 (6), p.4703-4717

2011

Link zum Volltext

Verfügbarkeit prüfen

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

Cancer biotherapy & radiopharmaceuticals, 1997-01, Vol.12 (3), p.177-186

1997

Link zum Volltext

Verfügbarkeit prüfen

Investigation on Phase Change Behavior of Paraffin Phase Change Material in a Spherical Capsule for Solar Thermal Storage Units

Heat transfer engineering, 2018-05, Vol.39 (9), p.775-783

2018

Link zum Volltext

Verfügbarkeit prüfen

Discovery and Preclinical Characterization of CC-95251, an Anti-SIRPα Antibody That Enhances Macrophage-Mediated Phagocytosis of Non-Hodgkin Lymphoma (NHL) Cells When Combined with Rituximab

Blood, 2021-11, Vol.138 (Supplement 1), p.2271-2271

2021

Link zum Volltext

Verfügbarkeit prüfen

Characterization of Inhibitory Anti-insulin-like Growth Factor Receptor Antibodies with Different Epitope Specificity and Ligand-blocking Properties

The Journal of biological chemistry, 2009-04, Vol.284 (15), p.10254-10267

2009

Link zum Volltext

Verfügbarkeit prüfen

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines

Blood, 2008-02, Vol.111 (3), p.1594-1602

2008

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2009: CC-90002 (anti-CD47 antibody) in vivo anti-tumor activity is associated with an increase in M1-polarized macrophages

Cancer research (Chicago, Ill.), 2017, Vol.77 (13_Supplement), p.2009-2009

2017

Link zum Volltext

Verfügbarkeit prüfen

A humanized anti-human CD154 monoclonal antibody blocks CD154–CD40 mediated human B cell activation

International immunopharmacology, 2001-02, Vol.1 (2), p.277-294

2001

Link zum Volltext

Verfügbarkeit prüfen

Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies

Cancer research communications, 2024-02, Vol.4 (2), p.505-515

2024

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4694: The humanized anti-CD47 monclonal antibody, CC-90002, has antitumor activity in vitro and in vivo

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4694-4694

2017

Link zum Volltext

Verfügbarkeit prüfen

Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs

Molecular cancer therapeutics, 2012-03, Vol.11 (3), p.572-581

2012

Link zum Volltext

Verfügbarkeit prüfen

Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine

International journal of oncology, 2013-08, Vol.43 (2), p.670-676

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 766: Galiximab disrupts the dysregulated NF-κB/YY1/Snail/BclXL circuit that regulates the resistance of B-NHL cell lines: Sensitization to chemo-immunotherapeutic drugs

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.766-766

2012

Link zum Volltext

Verfügbarkeit prüfen

Future of monoclonal antibodies in the treatment of hematologic malignancies

Cancer control, 2002-03, Vol.9 (2), p.152-166

2002

Link zum Volltext

Verfügbarkeit prüfen

CD80 (B7.1) Is Expressed On Both Malignant B Cells and Tumor Infiltrating T Cells in Non-Hodgkin's Lymphomas

Blood, 2009-11, Vol.114 (22), p.1953-1953

2009

Link zum Volltext

Verfügbarkeit prüfen

Galiximab Sensitizes Malignant Human B Cell Lines to Apoptosis by Chemotherapeutic Drugs

Blood, 2007-11, Vol.110 (11), p.3591-3591

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(42)

Publikationsform

Sprache

Englisch
(46)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(35)
Life Sciences & Biomedicine
(31)
Humans
(22)
Animals
(19)
Mice
(13)
Antibodies, Monoclonal - Immunology
(12)
Biological And Medical Sciences
(12)
Immunology
(11)
Oncology
(10)
Medical Sciences
(9)
Female
(8)
Antibodies, Monoclonal - Therapeutic Use
(7)
Aids/hiv
(6)
Immunotherapy
(6)
Medicine, Research & Experimental
(6)
Research & Experimental Medicine
(6)
Xenograft Model Antitumor Assays
(6)
Antibodies, Monoclonal - Pharmacology
(5)
Cell Line, Tumor
(5)
Antineoplastic Agents - Pharmacology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Structure of the human marker of self 5-transmembrane receptor CD47

Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody

Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma

Emerging antibody combinations in oncology

Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions

Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response

Stable IgG-like Bispecific Antibodies Directed toward the Type I Insulin-like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-tumor Activity

A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

Investigation on Phase Change Behavior of Paraffin Phase Change Material in a Spherical Capsule for Solar Thermal Storage Units

Discovery and Preclinical Characterization of CC-95251, an Anti-SIRPα Antibody That Enhances Macrophage-Mediated Phagocytosis of Non-Hodgkin Lymphoma (NHL) Cells When Combined with Rituximab

Characterization of Inhibitory Anti-insulin-like Growth Factor Receptor Antibodies with Different Epitope Specificity and Ligand-blocking Properties

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines

Abstract 2009: CC-90002 (anti-CD47 antibody) in vivo anti-tumor activity is associated with an increase in M1-polarized macrophages

A humanized anti-human CD154 monoclonal antibody blocks CD154–CD40 mediated human B cell activation

Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies

Abstract 4694: The humanized anti-CD47 monclonal antibody, CC-90002, has antitumor activity in vitro and in vivo

Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs

Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine

Abstract 766: Galiximab disrupts the dysregulated NF-κB/YY1/Snail/BclXL circuit that regulates the resistance of B-NHL cell lines: Sensitization to chemo-immunotherapeutic drugs

Future of monoclonal antibodies in the treatment of hematologic malignancies

CD80 (B7.1) Is Expressed On Both Malignant B Cells and Tumor Infiltrating T Cells in Non-Hodgkin's Lymphomas

Characterization of Inhibitory Anti-insulin-like Growth Factor Receptor Antibodies with Different Epitope Specificity and Ligand-blocking Properties: IMPLICATIONS FOR MECHANISM OF ACTION IN VIVO

Galiximab Sensitizes Malignant Human B Cell Lines to Apoptosis by Chemotherapeutic Drugs

Suchergebnisse filtern